دورية أكاديمية

Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group.

التفاصيل البيبلوغرافية
العنوان: Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group.
المؤلفون: Sierra, J., Conde, E., Iriondo, A., Brunet, S., Marín, J., Oteiza, J., Caballero, D., Martínez, F., León, A., García-Conde, J., Hernández-Navarro, F., Domingo, A., Carrera, D., Reverter, J., Richard, C., Zuazu, J., Baro, J., Rifón, J., Solano, C., Díaz-Mediavilla, J.
المصدر: Annals of Hematology; 1993, Vol. 67 Issue 3, p111-114, 4p
مصطلحات موضوعية: LYMPHOMA treatment, AUTOGRAFTS, BONE marrow, BONE marrow transplantation, COMPARATIVE studies, LACTATE dehydrogenase, LYMPHOMAS, RESEARCH methodology, MEDICAL cooperation, MULTIVARIATE analysis, PNEUMONIA, RESEARCH, EVALUATION research, TREATMENT effectiveness
مصطلحات جغرافية: SPAIN
مستخلص: To investigate the impact of frozen and non-frozen bone marrow on engraftment kinetics and disease outcome, 94 patients with non-Hodgkin's lymphoma (NHL) autografted with frozen marrow (F group) were retrospectively compared with 38 who received marrow stored at 4 degrees C or 10 degrees C (NF group). The major end points of this study were time to hematopoietic recovery and early toxicity; disease response, disease-free survival (DFS), and relapse rate were also analyzed. Upon comparison of the NF and F groups, no significant differences were found in the period of time required to achieve a granulocyte count higher than 0.5 x 10(9)/l (20 and 22 days, respectively, p = 0.47) or a platelet count higher than 20 x 10(9)/l (28 and 27 days, respectively, p = 0.54). In addition, both groups behaved similarly in respect to toxic death (NF group 13%, F group 22%, p = 0.36), response rate (complete remission rate 78% in both groups), DFS (NF group 48%, F group 49%, p = 0.66), and relapse rate (NF group 30, F group 19%, p = 0.37). This study confirms that nonfrozen bone marrow is useful to support patients with NHL treated with myeloablative therapies. [ABSTRACT FROM AUTHOR]
Copyright of Annals of Hematology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:09395555
DOI:10.1007/BF01701731